ATR
AptarGroup, Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · US
$126.85
−1.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.9B | 3.8B | 3.6B | 3.5B | 3.3B |
| Cost of Revenue | 2.8B | 2.7B | 2.2B | 2.2B | 2.2B |
| Gross Profit | 1.1B | 1.1B | 1.4B | 1.3B | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 325.3M | 105.1M | — | — | — |
| SG&A Expense | 634.8M | 499.9M | 582.2M | 565.8M | 544.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (335.1M) | — | 276.8M | 293.6M | 240.3M |
| Total Operating Expenses | 625.0M | 605.0M | 859.0M | 859.4M | 784.6M |
| Cost and Expenses | 3.4B | 3.3B | 3.1B | 3.1B | 2.9B |
| Operating Income (EBIT) | 486.5M | 512.3M | 496.5M | 404.0M | 379.3M |
| Non-Operating | |||||
| Interest Income | 13.4M | 11.7M | 12.1M | 4.4M | 2.7M |
| Interest Expense | 63.5M | 52.7M | 43.9M | 40.4M | 40.8M |
| Net Interest Income | (50.1M) | (41.1M) | (31.8M) | (36.0M) | (38.1M) |
| Other Non-Op Income/Expense | (32.1M) | (21.0M) | (26.7M) | (29.2M) | (44.6M) |
| Non-Operating Income (excl Interest) | (28.5M) | (31.8M) | (17.2M) | (11.2M) | 3.7M |
| EBT (Pre-Tax Income) | 454.5M | 491.4M | 469.8M | 374.8M | 334.7M |
| Income Tax Expense | 91.6M | 98.9M | 95.6M | 90.6M | 95.1M |
| Bottom Line | |||||
| Net Income | 362.5M | 392.8M | 374.5M | 284.5M | 239.3M |
| Earnings from Cont. Ops | 362.8M | 392.5M | 374.2M | 284.2M | 239.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 362.5M | 392.8M | 374.5M | 284.5M | 239.3M |
| Per Share | |||||
| Basic EPS | $5.60 | $5.97 | $5.65 | $4.34 | $3.66 |
| Diluted EPS | $5.53 | $5.88 | $5.53 | $4.25 | $3.59 |
| Revenue Per Share | $61.61 | $57.46 | $54.01 | $53.15 | $50.80 |
| Shares | |||||
| Basic Shares Outstanding | 63.8M | 65.7M | 66.3M | 65.6M | 65.4M |
| Diluted Shares Outstanding | 64.5M | 66.7M | 67.7M | 66.9M | 66.7M |
| Profitability Metrics | |||||
| EBITDA | 822.2M | 831.5M | 777.4M | 663.8M | 609.4M |
| D&A | 307.2M | 287.4M | 263.8M | 248.6M | 233.7M |
| EBIT | 515.0M | 544.1M | 513.7M | 415.2M | 375.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026